{"title":"1999-2020年美国脑血管疾病和药物使用相关死亡率上升趋势CDC WONDER的回顾性分析。","authors":"Anosh John, Faraz Azhar, Zishan Rahman, Dmitry Abramov","doi":"10.1159/000547512","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Substance use (SU) has been linked to cerebrovascular disease due to numerous pathophysiologic alterations. This study discusses the age, race, and demographics-related trends in mortality among US adults (≥25 years) with concomitant SU and cerebrovascular disease.</p><p><strong>Methods: </strong>The CDC WONDER database was used to access the mortality data. Age-adjusted mortality rates (AAMRs) per 100,000 population were calculated. Trends for age, sex, race, state, place of death, census region, and metropolitan status, along with annual percent change (APC) in AAMR, were calculated using the Joinpoint regression analysis.</p><p><strong>Results: </strong>From 1999 to 2020, 57,838 deaths occurred, with an overall AAMR of 1.23. The highest AAMRs were observed in adults aged 45-64 (1.8), men (1.85), the non-Hispanic American Indian/Alaska Native population (3.23), the District of Columbia (2.78), and nonmetropolitan areas (1.35).</p><p><strong>Conclusion: </strong>The rising mortality related to SU and cerebrovascular disease with notable sociodemographic and temporal disparities calls for further research and early interventions.</p>","PeriodicalId":9683,"journal":{"name":"Cerebrovascular Diseases","volume":" ","pages":"1-5"},"PeriodicalIF":1.5000,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Rising Trends in Cerebrovascular Disease and Substance Use-Related Mortality in the USA from 1999 to 2020: A Retrospective Analysis Using CDC WONDER.\",\"authors\":\"Anosh John, Faraz Azhar, Zishan Rahman, Dmitry Abramov\",\"doi\":\"10.1159/000547512\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Substance use (SU) has been linked to cerebrovascular disease due to numerous pathophysiologic alterations. This study discusses the age, race, and demographics-related trends in mortality among US adults (≥25 years) with concomitant SU and cerebrovascular disease.</p><p><strong>Methods: </strong>The CDC WONDER database was used to access the mortality data. Age-adjusted mortality rates (AAMRs) per 100,000 population were calculated. Trends for age, sex, race, state, place of death, census region, and metropolitan status, along with annual percent change (APC) in AAMR, were calculated using the Joinpoint regression analysis.</p><p><strong>Results: </strong>From 1999 to 2020, 57,838 deaths occurred, with an overall AAMR of 1.23. The highest AAMRs were observed in adults aged 45-64 (1.8), men (1.85), the non-Hispanic American Indian/Alaska Native population (3.23), the District of Columbia (2.78), and nonmetropolitan areas (1.35).</p><p><strong>Conclusion: </strong>The rising mortality related to SU and cerebrovascular disease with notable sociodemographic and temporal disparities calls for further research and early interventions.</p>\",\"PeriodicalId\":9683,\"journal\":{\"name\":\"Cerebrovascular Diseases\",\"volume\":\" \",\"pages\":\"1-5\"},\"PeriodicalIF\":1.5000,\"publicationDate\":\"2025-07-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cerebrovascular Diseases\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1159/000547512\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cerebrovascular Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000547512","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
Rising Trends in Cerebrovascular Disease and Substance Use-Related Mortality in the USA from 1999 to 2020: A Retrospective Analysis Using CDC WONDER.
Introduction: Substance use (SU) has been linked to cerebrovascular disease due to numerous pathophysiologic alterations. This study discusses the age, race, and demographics-related trends in mortality among US adults (≥25 years) with concomitant SU and cerebrovascular disease.
Methods: The CDC WONDER database was used to access the mortality data. Age-adjusted mortality rates (AAMRs) per 100,000 population were calculated. Trends for age, sex, race, state, place of death, census region, and metropolitan status, along with annual percent change (APC) in AAMR, were calculated using the Joinpoint regression analysis.
Results: From 1999 to 2020, 57,838 deaths occurred, with an overall AAMR of 1.23. The highest AAMRs were observed in adults aged 45-64 (1.8), men (1.85), the non-Hispanic American Indian/Alaska Native population (3.23), the District of Columbia (2.78), and nonmetropolitan areas (1.35).
Conclusion: The rising mortality related to SU and cerebrovascular disease with notable sociodemographic and temporal disparities calls for further research and early interventions.
期刊介绍:
A rapidly-growing field, stroke and cerebrovascular research is unique in that it involves a variety of specialties such as neurology, internal medicine, surgery, radiology, epidemiology, cardiology, hematology, psychology and rehabilitation. ''Cerebrovascular Diseases'' is an international forum which meets the growing need for sophisticated, up-to-date scientific information on clinical data, diagnostic testing, and therapeutic issues, dealing with all aspects of stroke and cerebrovascular diseases. It contains original contributions, reviews of selected topics and clinical investigative studies, recent meeting reports and work-in-progress as well as discussions on controversial issues. All aspects related to clinical advances are considered, while purely experimental work appears if directly relevant to clinical issues.